Download PDF
Diabetes aktuell 2018; 16(05): 190-198
DOI: 10.1055/a-0655-3997
Schwerpunkt | Typ2-Diabetes
© Georg Thieme Verlag Stuttgart · New York

Typ-2-Diabetes im Alter

Beispiel für eine patientenzentrierte medikamentöse Therapie
Dirk Müller-Wieland
Further Information

Publication History

Publication Date:
05 September 2018 (online)

Also available at
    Permissions and Reprints

ZUSAMMENFASSUNG

Im Alter wird die Prognose des Typ-2-Diabetes nicht so sehr durch die Qualität der Stoffwechseleinstellung bestimmt, sondern vielmehr durch die verbleibende Lebenszeit und vor allem durch die Funktionalität des Patienten. Wichtig ist es daher, Komorbiditäten zu berücksichtigen und kurzfristige Komplikationen (z. B. eine Hypoglykämie) strikt zu vermeiden. Die Diabetestherapie sollte primär die persönli-chen Lebensziele des Patienten im Fokus haben, seine Lebensqualität sowie den Erhalt der funktionellen Unabhängigkeit.

 

  • Literatur

  • 1 Jacobs E, Hoyer A, Brinks R. et al. Burden of mortality attributable to diagnosed diabetes: a nationwide analysis based on claims data from 65 million people in Germany. Diabetes Care 2017; 40: 1703-1709 doi:10.2337/dc17-0954
    CrossrefPubMedGoogle Scholar
  • 2 Danesh J. for The Emerging Risk Factors Collaboration. Association of cardiometabolic multimorbidity with mortality. JAMA 2015; 314: 52-60 doi:10.1001/jama.2015.7008
    CrossrefPubMedGoogle Scholar
  • 3 Marso SP, Daniels GH, Brown-Frandsen K. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311-322 doi:10.1056/NEJMoa1603827
    CrossrefPubMedGoogle Scholar
  • 4 Zinman B, Wanner C, Lachin JM. et al. Empagliflozin, Cardiovascular Putcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2016; 373: 2117-2128 doi:10.1056/NEJMoa1504720
    Google Scholar
  • 5 Fitchett D, Zinman B, Wanner C. et al. Heart failure outcomes with empagliflozin in patienets with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial investigators. Eur Heart J 2016; 37: 1526-1534 doi:10.1093/eurheartj/ehv728
    CrossrefPubMedGoogle Scholar
  • 6 Marx N, McGuire DK. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in highrisk patients with diabetes mellitus. Eur Heart J 2016; 37: 3192-3200 doi:10.1093/eurheartj/ehw110
    CrossrefPubMedGoogle Scholar
  • 7 McMurray JJV, Gerstein HC, Holman RR. et al. Heart failure: a cardiovascular outcome in diabetes hat can no longer be ignored. Lancet Diabetes Endocrinol 2014; 2: 843-851 doi: 10.1016/S2213-8587(14)70031-2
    CrossrefPubMedGoogle Scholar
  • 8 Bertoni AG, Hundley WG, Massing MW. et al. Heart Failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004; 27: 699-703 doi:10.2337/ diacare.27.3.699
    CrossrefPubMedGoogle Scholar
  • 9 Piepoli MF, Hoes AW, Agewall S. et al. European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2016; 37: 2315-2381 doi:10.1093/eurheartj/ ehw106
    CrossrefPubMedGoogle Scholar
  • 10 Lytwin Y, Bjornstad P, Udell PA. et al. Sodium Glucose Transporter-2 Inhibition in Heart Failure. Circulation 2017; 136: 1643-1658 doi:10.1161/CIRCULATIONAHA.117.030012
    CrossrefPubMedGoogle Scholar
  • 11 Hoogeven EK, Geleijnse JM, Giltay EJ. et al. Kidney function and specific mortality in 60-80 vears old post-myocardial infarction patients: A 10-year follow-up study. PloS ONE 2017; 12: e0171868 doi:10.1371/journal.pone.0171868
    CrossrefPubMedGoogle Scholar
  • 12 Wu B, Bell K, Stanford A. et al. Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns-NHANES 2007-2012. BMJ Open Diabetes Res Care 2016; 4: e000154 doi:10.1136/bmjdrc-2015-000154
    PubMedGoogle Scholar
  • 13 Wanner C, Inzucchi SE, Lachin JM. et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375: 323-334 doi: 10.1056/NEJMoa1515920
    CrossrefPubMedGoogle Scholar
  • 14 Quartuccio M, Buta B, Kalyani RR. Comparative effectiveness for glycemic control in older adults with diabetes. Curr Geri Rep 2017 6: 175-186 doi: 10.1007/s13670-017-0215-z
    Google Scholar
  • 15 Farrell B, Black C, Thompson W. et al. Deprescribing antihypergylcemic agents in older persons. Evidence-based clinical practice guideline. Can Fam Physician 2017; 63: 832-843
    PubMedGoogle Scholar
  • 16 Ellis G, Whitehead MA, Robinson D. et al. Comprehensive geriatric assessment for older adults admitted to hospital: meta-analysis of randomised controlled trials. BMJ 2011; 343: d6553 doi:10.1136/bmj.d6553
    CrossrefPubMedGoogle Scholar
  • 17 American Diabetes Association. 6. Glycemic Targets. Diabetes Care 2017; 40 Suppl (Suppl. 01) S48-S56 doi:10.2337/ dc17-S009
    PubMedGoogle Scholar
  • 18 Bremer JP, Jauch-Chara K, Hallschmid M. et al. Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care 2009; 32: 1513-1517 doi: 10.2337/dc09-0114
    CrossrefPubMedGoogle Scholar
  • 19 Lipska KJ, Ross JS, Miao Y. et al. Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. JAMA Intern Med 2015; 175: 356-362 doi: 10.1001/ jamainternmed.2014.7345
    CrossrefPubMedGoogle Scholar
  • 20 Huang ES, Laitererapong N, Liu JY. et al. Rates of complications and mortality in older patients with diabetes mellitus: the diabetes and aging study. JAMA Intern Med 2014; 174: 251-258 doi:10.1001/jamainternmed.2013.12956
    CrossrefPubMedGoogle Scholar